Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Non-hodgkin Lymphoma”

296 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 296 results

Testing effectiveness (Phase 2)Looking for participantsNCT06716658
What this trial is testing

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Who this might be right for
Lymphoma, T-CellNK-LGL LeukemiaT-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China 48
Testing effectiveness (Phase 2)Study completedNCT00244985
What this trial is testing

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Roswell Park Cancer Institute 42
Testing effectiveness (Phase 2)Study completedNCT00720876
What this trial is testing

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 30
Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Large-scale testing (Phase 3)Ended earlyNCT04745832
What this trial is testing

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Who this might be right for
Follicular Lymphoma (FL)Non Hodgkin LymphomaMarginal Zone Lymphoma
MEI Pharma, Inc. 82
Large-scale testing (Phase 3)Active Not RecruitingNCT03984448
What this trial is testing

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Who this might be right for
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble-Expressor Lymphoma+5 more
National Cancer Institute (NCI) 363
Early research (Phase 1)WithdrawnNCT05934097
What this trial is testing

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaTransformed Indolent Non-Hodgkin's LymphomaFollicular Lymphoma+2 more
Fate Therapeutics
Testing effectiveness (Phase 2)UnknownNCT00927797
What this trial is testing

Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)

Who this might be right for
Immunocytoma/Morbus WaldenströmB-Cell Non-Hodgkin's LymphomaB-Cell Chronic Lymphocytic Leukemia
Heidelberg University 185
Testing effectiveness (Phase 2)Study completedNCT03019640
What this trial is testing

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Mantle Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+4 more
M.D. Anderson Cancer Center 22
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Early research (Phase 1)WithdrawnNCT02640833
What this trial is testing

Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNon-Hodgkin Lymphoma
AbbVie
Large-scale testing (Phase 3)Study completedNCT00877006
What this trial is testing

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Who this might be right for
Non-Hodgkin's LymphomaMantle Cell Lymphoma
Teva Branded Pharmaceutical Products R&D, Inc. 447
Very early researchUnknownNCT04626739
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Who this might be right for
Refractory Indolent Adult Non-Hodgkin Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 100
Early research (Phase 1)Active Not RecruitingNCT06824701
What this trial is testing

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah 24
Not applicableUnknownNCT03265158
What this trial is testing

Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0

Who this might be right for
Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)
Royal Marsden NHS Foundation Trust 108
Testing effectiveness (Phase 2)Study completedNCT02499003
What this trial is testing

GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin
Johannes Gutenberg University Mainz 70
Testing effectiveness (Phase 2)Study completedNCT00081809
What this trial is testing

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

Who this might be right for
Lymphoma, FollicularLymphoma, Small Lymphocytic
Agenus Inc. 35
Large-scale testing (Phase 3)Study completedNCT01938001
What this trial is testing

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 358
Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Next Page